Here, we report on the phase 2 POLARIS trial (NCT03911869), which prospectively evaluated encorafenib in combination with binimetinib in BRAF/MEK inhibitor-naive patients with BRAF V600-mutant melanoma with asymptomatic brain metastases, including those who had progressed on prior checkpoint immunotherapy. This evidence concerns the gene MAP2K7 and melanoma.